| [1] |
Chen W, Zheng R, Baade PD，et al.Cancer statistics in China，2015 [J]．CA Cancer J Clin，2016，66(2)：115-132.
|
| [2] |
李依敏，苏思贞，朱静，等．乳腺癌靶向治疗药物治疗研究进展 [J]．山东医药，2017，57(9)：107-109.
|
| [3] |
中国抗癌协会乳腺癌专业委员会．Her-2阳性乳腺癌临床诊疗专家共识 [J]．中国癌症杂志，2012，22(4)：314-318.
|
| [4] |
江泽飞，邵志敏，徐兵河．人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识2016 [J]．中华医学杂志，2016，96(14)：1091-1096.
|
| [5] |
Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017 [J]. Ann Oncol, 2017, 28(8): 1700-1712.
|
| [6] |
U．S.Food and Drug Administration.FDA grants regular approval to pertuzumab for adjuvant treatment of HER2-positive breast cancer[EB/OL]．[2019-07-01].
URL
|
| [7] |
Gianni L, Pienkowski T, Im YH，et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER-2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J]. Lancet Oncol, 2016, 17(6): 791-800.
|
| [8] |
von Minckwitz G, Procter M, de Azambuja E，et al.Adjuvant pertuzumab and trastuzumab in eraly HER-2-positive breast cancer [J]．N Engl J Med，2017，377(2)：122-131.
|
| [9] |
Swain SM, Baselga J, Kim SB，et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer [J]．N Engl J Med, 2015, 372(8): 724-734.
|
| [10] |
Loi S,，Giobbe-Hurder A,，Gombos A，et al. PhaseⅠb/Ⅱstudy evaluating the efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER-2-positive metastatic breast cancer：Results from the PANACEA (IBCSG45-13/KEYNOTE-014) study[EB/OL]．[2019-06-01].
URL
|
| [11] |
Rugo HS, Im SA, Cardoso F，et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2 positive advanced breast cancer: a phase 3 randomized clinical trial[J]. JAMA Oncol，2021，7(4)：573584.
|
| [12] |
vonMinckwitz G, Huang CS, Mano MS，et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer [J]．N Engl J Med，2019，380(7)：617-628.
|
| [13] |
Sakai H, Tsurutani J, Iwasa T, et al.HER-2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER-2-positive metastatic breast cancer [J]．Breast Cancer，2018，25(5): 605-613.
|
| [14] |
Hongbin W, Wenqin W, Yanping X，et al.Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells [J]．Cancer Sci，2017，108(7)：1458-1468.
|
| [15] |
U．S.Food and Drug Administration.FDA approves new treatment to reduce the risk of breast cancer returning [EB/OL]．[2019-07-01]．
URL
|
| [16] |
Chan A, Delaloge S, Holmes FA，te al.Neratinib after trastuzumab-based adjuvant therapy in patients with HER-2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled，phase 3 trial [J]. Lancet Oncol, 2016, 17(3): 367-377.
|
| [17] |
Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER-2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebocontrolled, phase 3 trial [J]. Lancet Oncol, 2017, 18(12): 1688-1700.
|
| [18] |
Fei Ma, Quchang Ouyang, Wei Li，et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase Ⅱ study [J]．J Clin Oncol，2019，37(29)：2610-2619.
|
| [19] |
Xu B, Yan M, Ma F，et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial [J]. Lancet Oncol，2021，22(3)：351-360.
|
| [20] |
Zhou Z, Qiao JX, Shetty A，et al. Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy [J]．Cell Mol Life Sci，2014，71(8)：1549.
|
| [21] |
金科，赵丹，杨林，等．CDK4/6抑制剂联合内分泌治疗对乳腺癌细胞miRNA表达水平的影响 [J]. 现代肿瘤医学，2019，27(5)：723-727.
|
| [22] |
国家药品监督管理局.2018年审评通过的优先审评药品名单[EB/OL]．[2019-07-01].
URL
|
| [23] |
Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first line therapy for HR-positive, advanced breast cancer [J]. N Engl J Med, 2016, 375(18)：1738-1748.
|
| [24] |
Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormonereceptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial [J]. Lancet Oncol, 2018, 19(7)：904-915.
|
| [25] |
Slamon DJ, Neven P, Chia S，et al.Phase Ⅲ randomized study of ribociclib and Fulvestrant in hormone receptor-positive，human epidermal growth factor receptor 2-negative advanced breast cancer：MONALEESA-3 [J]．J Clin Oncol，2018，36(24)：2465-2472.
|
| [26] |
Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer [J]. N Engl J Med，2019，381(4)：307-316.
|
| [27] |
O’Leary B, Cutts RJ, Liu Y, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial[J]. Cancer Discov, 2018，8(11)：1390-1403.
|
| [28] |
Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer [J]．N Engl J Med，2015，373(3)：209-219.
|
| [29] |
Hares SH, Harvey AJ. mTOR function and therapeutic targeting in breast cancer [J]．Am J Cancer Res，2017，7(3)：383-404.
|
| [30] |
Paplomata E, O’Regan R．The PI3K/AKT/mTOR pathway in breast cancer：targets，trials and biomarkers [J]．Ther Adv Med Oncol，2014，6(4)：154-166.
|
| [31] |
Tesch H, Stoetzer O, Decker T，et al.Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase ⅢB 4EVER trial [J]．Int J Cancer，2019，144(4)：877-885.
|
| [32] |
Jones RH, Casbard A, Carucci M，et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial[J]. Lancet Oncol，2020，21(3)：345-357.
|
| [33] |
Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry[J]. Cancer，2007，109(9)：1721-1728.
|
| [34] |
国家药品监督管理局．首个国产PD-1抗体药物特瑞普利单抗注射液获批上市 [EB/OL]．[2018-12-17]．
URL
|
| [35] |
黄述斌，侯永微，李松梅，等．乳腺癌组织及间质浸润淋巴细胞中PD-L1的表达及其意义 [J]．临床与实验病理学杂志，2017，33(1)：63-67.
|
| [36] |
Cimino-Mathews A, Thompson E, Taube J M，et a1.PD-L1(B7-H1 ) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas [J]．Human Pathol，2016，47(1)：52-63.
|
| [37] |
Nanda R, Specht J, Dees C，et al.KEYNOTE-012：long-lasting response in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC) [J]. Cancer Res，2017, 77(4 Suppl)：P6-10-03.
|
| [38] |
Adams S, Loi S, Toppmeyer D, et at. Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC)：preliminary data from KEYNOTE-086 cohort B [J]．J Clin Oncol，2017，35(15 Suppl)：1088.
|
| [39] |
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer [J]. N Engl J Med，2018，379(22)：2108-2121.
|
| [40] |
Schmid P, Rhgo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion 130): updated efficacy, from a randomised，double-blind placebo-controlled，phase 3 trial [J]. Lancet Oncol, 2020, 21(1): 44-59.
|
| [41] |
Schmid P, Adams S, Rugo HS，et al.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer [J]．N Eng J Med，2018，379(22)：2108-2121.
|
| [42] |
U．S. Food and Drug Administration. FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer[EB/OL]．[2019-03-08]．
URL
|
| [43] |
Sikov WM, Berry DA, Perou CM，et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603 (Alliance) [J]. J Clin Oncol，2015，33(1)：13-21.
|
| [44] |
Symonds L, Linden H, Gadi V，et al.Combined targeted therapies for first-line treatment of metastatic triple negative breast cancer-a phase Ⅱ trial of weekly nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib [J]．Clin Breast Cancer，2019，19(2)：e283-e296.
|
| [45] |
Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo[J]. Cancer Sci，2011，102(7)：1374-1380.
|
| [46] |
鲁凯莉．阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效探讨 [J]．中国处方药，2018，16(6)：75-76.
|
| [47] |
Li YH, Zhou Y, Wang YW，et al.Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study [J]．Medicine (Baltimore)，2018，97 (36)：e12222.
|
| [48] |
Lee LJ, Alexander B, Schnitt SJ，et al.Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers [J]．Cancer，2011，117( 14): 3093-3100.
|
| [49] |
Hu T, Liu C, Li Q，et al. Tapatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer：Case report and literature review [J]．Medicine (Baltimore), 2018, 97(15)：e0349.
|
| [50] |
Li T, Wang SB, Lei KJ，et al. Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer：A case report [J]．Medicine (Baltimore)，2019，98(4)：e14182.
|
| [51] |
张秀伟，钟文，魏士博，等．三阴性乳腺癌与PARP1表达相关性的Meta分析 [J]．现代肿瘤医学，2017，25(6)：893-896.
|
| [52] |
Vinayak S, Tolaney SM, Schwartzberg L，et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer[J]. JAMA Oncol，2019，5(8)：1132-1140.
|
| [53] |
Pietri E, Conteduca V, Andreis D, et al. Androgen receptor signaling pathways as a target for breast cancer treatment [J]. Endocr Relat Cancer，2016，23(10)：R485-498.
|
| [54] |
Lyons T, Gucalp A, Arumov A, et al. Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer[J]. J Clin Oncol，2018，36(15 suppl)：531.
|
| [55] |
Traina TA, Miller K, Yardley DA, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer [J]. J Clin Oncol, 2018，36(9)：884-890.
|
| [56] |
Schmid P, Abraham J, Chan S, et al. AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase Ⅱ trial[J]. J Clin Oncol，2018，36(15 suppl)：1007.
|